Show simple item record

More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma

dc.contributor.authorJun, Tomi W.
dc.contributor.authorYeh, Ming‐lun
dc.contributor.authorYang, Ju Dong
dc.contributor.authorChen, Vincent L.
dc.contributor.authorNguyen, Pauline
dc.contributor.authorGiama, Nasra H.
dc.contributor.authorHuang, Chung‐feng
dc.contributor.authorHsing, Ann W.
dc.contributor.authorDai, Chia‐yen
dc.contributor.authorHuang, Jee‐fu
dc.contributor.authorChuang, Wan‐long
dc.contributor.authorRoberts, Lewis R.
dc.contributor.authorYu, Ming‐lung
dc.contributor.authorNguyen, Mindie H.
dc.date.accessioned2018-05-15T20:16:22Z
dc.date.available2019-07-01T14:52:17Zen
dc.date.issued2018-05
dc.identifier.citationJun, Tomi W.; Yeh, Ming‐lun ; Yang, Ju Dong; Chen, Vincent L.; Nguyen, Pauline; Giama, Nasra H.; Huang, Chung‐feng ; Hsing, Ann W.; Dai, Chia‐yen ; Huang, Jee‐fu ; Chuang, Wan‐long ; Roberts, Lewis R.; Yu, Ming‐lung ; Nguyen, Mindie H. (2018). "More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma." Liver International 38(5): 895-902.
dc.identifier.issn1478-3223
dc.identifier.issn1478-3231
dc.identifier.urihttps://hdl.handle.net/2027.42/143802
dc.description.abstractBackground & AimsAlthough hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remain major risk factors for hepatocellular carcinoma (HCC), nonâ viral causes of HCC, particularly nonâ alcoholic fatty liver disease (NAFLD), are becoming increasingly prevalent. The aim of this study was to compare the clinical characteristics and survival of cryptogenic and viral HCC.MethodsWe conducted a retrospective cohort study involving 3878 consecutive HCC patients seen at two tertiary centres in the United States and one in Taiwan from 2004 to 2014. We compared the clinical characteristics, treatment and survival of patients by underlying aetiology: cryptogenic (n = 696), HBV (n = 1304) or HCV (n = 1878).ResultsCirrhosis was present in 66.8% of the cryptogenic HCC patients, compared with 74.7% of HBVâ related HCC (HBVâ HCC) (P = .001) and 85.9% of HCVâ HCC (P < .001). Compared to viral HCC, cryptogenic HCC patients presented with larger tumours and at later stages of disease. Fiveâ year overall survival was 16.3% among cryptogenic HCC patients compared with 31.9% among HBVâ HCC patients and 27.7% among HCVâ HCC patients (P < .001 for both by the logâ rank test). HCC aetiology was not an independent predictor of survival, though ethnicity, cirrhosis status, meeting Milan criteria and treatment allocation were.ConclusionsCompared with viral HCC patients, those with cryptogenic HCC had lower prevalence of cirrhosis, were diagnosed with larger tumours at more advanced stages of disease, and had poorer overall survival. Additional efforts are needed to identify patients at risk of cryptogenic HCC and to identify cryptogenic HCC at earlier stages of disease.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherhepatocellular carcinoma
dc.subject.othercryptogenic HCC
dc.subject.otherhepatitis B
dc.subject.otherhepatitis C
dc.titleMore advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/143802/1/liv13613_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/143802/2/liv13613.pdf
dc.identifier.doi10.1111/liv.13613
dc.identifier.sourceLiver International
dc.identifier.citedreferenceMargini C, Dufour JF. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment. Liver Int. 2016; 36: 317 â 324.
dc.identifier.citedreferenceFitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived With disability, and disabilityâ adjusted lifeâ years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2016; 3: 524 â 548.
dc.identifier.citedreferenceChiang Câ J, Lo Wâ C, Yang Yâ W, You Sâ L, Chen Câ J, Lai Mâ S. Incidence and survival of adult cancer patients in Taiwan, 2002â 2012. J Formos Med Assoc. 2016; 115: 1076 â 1088.
dc.identifier.citedreferenceSiegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66: 7 â 30.
dc.identifier.citedreferencePerz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006; 45: 529 â 538.
dc.identifier.citedreferencePowell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a followâ up study of fortyâ two patients for up to 21 years. Hepatology. 1990; 11: 74 â 80.
dc.identifier.citedreferenceWhite DL, Kanwal F, Elâ Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012; 10: 1342 â 1359.
dc.identifier.citedreferenceYounossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011; 9: 524 â 530; quiz e60.
dc.identifier.citedreferenceYounossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonâ alcoholic fatty liver diseaseâ metaâ analytic assessment of prevalence, incidence and outcomes. Hepatology. 2015; 64: 73 â 84.
dc.identifier.citedreferenceBruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53: 1020 â 1022.
dc.identifier.citedreferenceBaffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in nonâ alcoholic fatty liver disease: an emerging menace. J Hepatol. 2012; 56: 1384 â 1391.
dc.identifier.citedreferenceKawada N, Imanaka K, Kawaguchi T, et al. Hepatocellular carcinoma arising from nonâ cirrhotic nonalcoholic steatohepatitis. J Gastroenterol. 2009; 44: 1190 â 1194.
dc.identifier.citedreferenceParadis V, Zalinski S, Chelbi E, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 2009; 49: 851 â 859.
dc.identifier.citedreferenceTokushige K, Hashimoto E, Horie Y, Taniai M, Higuchi S. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol. 2011; 46: 1230 â 1237.
dc.identifier.citedreferenceMittal S, Sada YH, Elâ Serag HB, et al. Temporal trends of nonalcoholic fatty liver diseaseâ related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol. 2015; 13: 594 â 601.
dc.identifier.citedreferencePiscaglia F, Svegliatiâ Baroni G, Barchetti A, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology. 2016; 63: 827 â 838.
dc.identifier.citedreferenceGiannini EG, Marabotto E, Savarino V, et al. Hepatocellular carcinoma in patients with cryptogenic cirrhosis. Clin Gastroenterol Hepatol. 2009; 7: 580 â 585.
dc.identifier.citedreferenceFarrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006; 43 ( 2 Suppl 1 ): S99 â S112.
dc.identifier.citedreferenceBugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002; 123: 134 â 140.
dc.identifier.citedreferenceOng J, Younossi ZM, Reddy V, et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl. 2001; 7: 797 â 801.
dc.identifier.citedreferenceSimmons O, Fetzer DT, Yokoo T, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther. 2017; 45: 169 â 177.
dc.identifier.citedreferenceKolly P, Dufour Jâ F. Surveillance for hepatocellular carcinoma in patients with NASH. Diagnostics (Basel). 2016; 6: pii: E22.
dc.identifier.citedreferenceYasui K, Hashimoto E, Komorizono Y, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011; 9: 428 â 433; quiz e50.
dc.identifier.citedreferenceTakuma Y, Nouso K. Nonalcoholic steatohepatitisâ associated hepatocellular carcinoma: our case series and literature review. World J Gastroenterol. 2010; 16: 1436 â 1441.
dc.identifier.citedreferenceHsu Câ Y, Lee Yâ H, Liu Pâ H, et al. Decrypting cryptogenic hepatocellular carcinoma: clinical manifestations, prognostic factors and longâ term survival by propensity score model. PLoS One. 2014; 9: e89373.
dc.identifier.citedreferenceYounossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015; 62: 1723 â 1730.
dc.identifier.citedreferenceWong DKH, Huang FY, Lai CL, et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology. 2011; 54: 829 â 836.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.